Literature DB >> 23847383

Selumetinib shows promise in metastatic uveal melanoma.

.   

Abstract

Compared with temozolomide chemotherapy, the MEK inhibitor selumetinib extended progression-free survival by nearly 9 weeks in patients with melanoma of the eye participating in a phase II trial, making it the first effective drug for the rare disease.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23847383     DOI： 10.1158/2159-8290.CD-NB2013-086

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  7 in total

Review 1.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

2.  Clinical presentation and management of uveal melanoma.

Authors:  Abelardo Rodríguez; Alfonso Dueñas-Gonzalez; Sarai Delgado-Pelayo
Journal:  Mol Clin Oncol       Date:  2016-09-27

Review 3.  Recent developments in prognostic and predictive testing in uveal melanoma.

Authors:  Matthew G Field; J William Harbour
Journal:  Curr Opin Ophthalmol       Date:  2014-05       Impact factor: 3.761

4.  A molecular revolution in uveal melanoma: implications for patient care and targeted therapy.

Authors:  J William Harbour; Daniel L Chao
Journal:  Ophthalmology       Date:  2014-01-28       Impact factor: 12.079

Review 5.  Understanding the biology of melanoma and therapeutic implications.

Authors:  Ryan J Sullivan; David E Fisher
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

6.  Artesunate combined with verteporfin inhibits uveal melanoma by regulation of the MALAT1/yes-associated protein signaling pathway.

Authors:  Xudong Jiu; Yang Liu; Jin Wen
Journal:  Oncol Lett       Date:  2021-06-09       Impact factor: 2.967

Review 7.  The genetics of uveal melanoma: current insights.

Authors:  Hildur Helgadottir; Veronica Höiom
Journal:  Appl Clin Genet       Date:  2016-09-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.